Enveric Receives Patent For Psilocybin Molecules [Green Market Report]
Wednesday, September 20, 2023 1 min read
Key Takeaway: Enveric Biosciences has been granted U.S. Patent No. 11,752,130 for its EVM301 Series of carboxylated psilocybin derivatives. This patent is significant as it pertains to potential treatments for mental health disorders, potentially strengthening the company's market position in this therapeutic area.
Market Sentiment Analysis
POSITIVE FACTORS
Enveric received a new patent for its psilocybin molecules.
The patent could enhance the company's position in mental health treatments.
EVM301 Series shows potential for addressing mental health disorders.
Full Press Release Details
Enveric Biosciences (NASDAQ: ENVB) announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,752,130, titled “Carboxylated Psilocybin Derivatives and Methods of Using,” pertaining to the Company’s EVM301 Series of molecules being developed as potential treatments for mental health disorders.
Full Story
Frequently Asked Questions
What patent did Enveric receive?
Enveric received U.S. Patent No. 11,752,130 for carboxylated psilocybin derivatives.
What is the focus of the EVM301 Series?
The EVM301 Series focuses on potential treatments for mental health disorders.
Who issued the patent for Enveric's molecules?
The United States Patent and Trademark Office issued the patent.
What is the significance of this patent for Enveric?
The patent could enhance Enveric's position in the mental health treatment market.